Histological effects of short term endocrine therapy on prostatic cancer

Japanese Journal of Urology

Volumn 87, Issue 7, 1996, Pages 977-985

  Irisawa, Chiharu ^a   Yoshimura, Yasukuni ^a   Yokota, Takashi ^a   Yamaguchi, Osamu ^a   Kondou, Yoshimasa ^b   Hamasaki, Takashi ^b   Yamad, Youji ^b   Kurosu, Seiichi ^b   Chiba, Ryuuichi ^b  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b FUKUSHIMA ROSAI HOSPITAL   (Japan)

Author keywords

endocrine therapy; histological effects; prostatic cancer

Indexed keywords

FOSFESTROL;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CELL DEGENERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PROSTATE CANCER; PROSTATECTOMY;

EID: 0029788810     PISSN: 00215287     EISSN: None     Source Type: Journal    
DOI: 10.5980/jpnjurol1989.87.977     Document Type: Article

References (19)

1. Huggins, G. and Hodges, C.V.: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1, 292-297, 1941.
2. Schenken, J.R., Burns, E.L. and Kahle, P.J : The effect of diethylstilbestrol and diethylstilbestrol dipropionate on carcinoma of the prostate gland. 2. Cytologic changes following treatment. J. Urol., 48, 99-112, 1942.
3. Fergusson, J.D. and Franks, L.M.: The response prostatic carcinoma to estrogen treatment. Brit. J. Surg., 40, 422-428, 1953.
4. Kahle, P.J., Schenken, J.R. and Burns, E.L : Clinical and pathologic effects of diethylstilbestrol and diethylstilbestrol dipropionate on carcinoma of the prostate gland. A continuing study. J. Urol., 50, 711-732, 1943.
5. Dhom, G. and Degro, S.: Therapy of prostatic cancer and histpathologic follow-up. Prostate, 3, 531-542, 1982.
6. Isaka, S., Teshima, S., Akakura, K., Igarashi, T., Murakami, S. and Shimazaki, J.: Histrogical effects of endocrine therapy to prostatic cancer in relation with clinical course. Jpn. J. Clin. Oncol., 19, 258-264, 1989.
7. Tetu, B., Srigley, J.R., Boivin, J.-C., Dupnt, A., Monfette, G., Pinault, S. and Labrie, F.: Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. Am. J. Surg., Pathol., 15, 111-120, 1991.
8. Hellstrom, M., Haggman, M., Brandstedt, S., Tolle, M., Pedersen, K., Jarlsfeldt, I., Wijkstrom, H. and Busch, C.: Histopathological changes in androgendeprived localized prostatic cancer. Eur. Urol., 24, 461-465, 1993.
9. Wim, M., Aziz, A.E., Hein, P., Erik, K.V., Luc, V.B. and Joseph, M.L.: Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies. Cancer, 74, 3164-3175, 1994.
10. Gleason, D.F.: Classification of prostatic carcinomas Cancer Chemother. Rep., 50, 125-128, 1966.
11. Murphy, W.M., Soloway, M.S. and Barrows, G. H.: Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer, 68, 821-828, 1991.
12. Kyprianou, N.: Apoptosis: Therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer. World J. Urol., 12, 299-303, 1994.